Ignite Creation Date:
2024-05-06 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04721470
Status:
COMPLETED
Last Update Posted:
2021-01-22
First Post:
2021-01-20
Brief Title:
Combined Therapy for Hepatocellular Carcinoma 3-5 cm
Sponsor:
Zagazig University
Organization:
Zagazig University
Study Overview
Official Title:
Combined Therapy With Conventional Trans-arterial Chemoembolization cTACE and Microwave Ablation MWA for Hepatocellular Carcinoma 3-5 cm
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization cTACE microwave ablation MWA versus only TACE or MWA for treatment of hepatocellular carcinoma HCC 3-5 cm
Detailed Description:
This study aims to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization cTACEmicrowave ablation MWA versus only TACE or MWA for treatment of hepatocellular carcinoma HCC 3-5 cm
This randomized controlled trial screened 278 patients with HCC 3-5 cm Patients were randomized into three groups 90 underwent TACE Group 1 95 underwent MWA Group 2 and 93 underwent combined therapy Group 3 Patients were followed-up with contrast-enhanced CT or MRI Images were evaluated and compared for treatment response and adverse events based on modified response evaluation criteria in solid tumor Serum alpha-fetoprotein AFP concentration was measured at baseline and during every follow-up visit
This randomized controlled trial screened 278 patients with HCC 3-5 cm Patients were randomized into three groups 90 underwent TACE Group 1 95 underwent MWA Group 2 and 93 underwent combined therapy Group 3 Patients were followed-up with contrast-enhanced CT or MRI Images were evaluated and compared for treatment response and adverse events based on modified response evaluation criteria in solid tumor Serum alpha-fetoprotein AFP concentration was measured at baseline and during every follow-up visit
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None